Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo

This study has been terminated.
(Slow inclusion resulting in premature termination due to logistics)
Sponsor:
Collaborator:
IMK Fonden
Information provided by:
Hvidovre University Hospital
ClinicalTrials.gov Identifier:
NCT00286936
First received: February 3, 2006
Last updated: August 29, 2011
Last verified: September 2006
  Purpose

To examine the influence of regular hypnotic therapy on the incidence of delirium after hip fracture surgery


Condition Intervention Phase
Hip Fracture
Delirium
Drug: Zolpidem
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo

Resource links provided by NLM:


Further study details as provided by Hvidovre University Hospital:

Primary Outcome Measures:
  • Incidence and severity of postoperative delirium

Secondary Outcome Measures:
  • Sleep quality
  • mobilization
  • loss of functional ability
  • length of stay
  • sedation
  • nocturnal nursing events

Estimated Enrollment: 96
Study Start Date: February 2004
Study Completion Date: January 2007
Detailed Description:

Delirium is prevalent after hip fracture surgery. Delirium has been linked to postoperative sleep disturbances. Zolpidem is a non-benzodiazepine hypnotic that preserves REM sleep. The present study investigates the incidence of delirium in hip fracture patients randomized to Zolpidem treatment 5 mg vs placebo in the perioperative phase.

  Eligibility

Ages Eligible for Study:   70 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Primary hip fracture, no substance abuse, no regular opioid, corticosteroid or benzodiazepine therapy, hepatic insufficiency, myastenia gravis, allergies to drug components

Exclusion Criteria:

  • Severe respiratory insufficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00286936

Locations
Denmark
Hvidovre University Hospital
Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
IMK Fonden
Investigators
Study Director: Nicolai B Foss, MD Hvidovre University Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00286936     History of Changes
Other Study ID Numbers: HHSG-RCT-05
Study First Received: February 3, 2006
Last Updated: August 29, 2011
Health Authority: Denmark: Ministry of Health

Keywords provided by Hvidovre University Hospital:
Hip fracture
delirium
sleep disturbance
hypnotic

Additional relevant MeSH terms:
Delirium
Fractures, Bone
Hip Fractures
Confusion
Delirium, Dementia, Amnestic, Cognitive Disorders
Femoral Fractures
Hip Injuries
Leg Injuries
Mental Disorders
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms
Wounds and Injuries

ClinicalTrials.gov processed this record on November 19, 2014